Erratum to: Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease

Affiliations

• ¹ Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, ON, Canada. [email protected].
• ² Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR, USA. [email protected].
• ³ Division of Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
• ⁴ Department of Pathology, University Health Network, Toronto, ON, Canada.
• ⁵ Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
• ⁶ Department of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA, USA.
• ⁷ Department of Pathology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
• ⁸ Division of Surgical Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Centre, Toronto, ON, Canada. [email protected].